Over 3 Million Dollars Available for Young Scientists

06.19.14 | By

For nearly 50 years the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for scientists to become leaders in their organizations and fields. Their programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry. Are you one of them?

First Technology Pilot Program Shares Perspective of Sickle Cell Disease Community with FDA

06.18.14 | By

In the guest blog below, Michele Lloyd-Puryear, Special Consultant to Genetic Alliance, discusses key findings from a patient-driven data collection effort intended to complement the Food and Drug Administration’s (FDA) patient-focused drug development initiative which was part of the most recent reauthorization of the Prescription Drug User Fee Act.

Patient Reported Outcomes as a Means to Reaching Effective Quality Measurement

06.17.14 | By

A recent Roundtable in Washington D.C. underscored why, with the growing focus on value-based payment in health care, it’s more important than ever to focus on the patient. We can’t advance patient-centered care if we aren’t measuring and incentivizing what matters to patients. We have begun to see this shift in the premarket arena via patient-focused drug development and in comparative effectiveness research at the Patient-Centered Outcomes Research Institute.

Week in Review: The Obstacles to Patient Care Under HIX

06.13.14 | By

For our nation’s most vulnerable patients, access to necessary medicines to treat and even cure the diseases they are battling every day is critical. Improved patient health relies on the innovative treatments, and this week we focused on the importance of ensuring those medicines make it into the hands of patients in need.

Working Together for the Greater Good: The Current State of the Collaborative Research Ecosystem in Oncology

06.12.14 | By

Keeping the spirit of innovation alive in the oncology field is paramount to future scientific advances and finding cures. An essential element of innovation is collaboration. Relevant stakeholders coming together and pooling collective knowledge together can ignite the fire that becomes the next big thing to improve the lives of cancer patients.

Some Health Insurance Exchange Plans Put All Treatments for Certain Diseases on Top Cost-Sharing Tier

06.11.14 | By

This morning at the National Press Club, PhRMA CEO John J. Castellani joined patient groups to release new research from Avalere Health.

Broader Discussion on Cancer Care Spending Needed

06.10.14 | By

If we want to have an honest discussion around cost, we must do so in a way that includes the entire spectrum of cancer care and not focused solely on the cost of cancer medicines.

A Look at What Is Coming Through the Pipeline for Cancer Research: A Q&A with Astellas’ Josh Schafer

06.09.14 | By

With the recent conclusion of ASCO, we sat down with Josh Schafer, Astellas’ Vice President of Oncology Marketing Strategy, to get his perspective on the current state of affairs surrounding cancer research.

Increased Collaboration and Investment in Science and Regulatory Workforce Necessary to Advance Scientific Discovery

06.09.14 | By

PhRMA strongly supports the goals of the House Energy and Commerce Committee’s 21st Century Cures initiative that seeks to accelerate the discovery, development and delivery of new treatments and potential cures to patients.

Canada’s IP Policies Need New Look

06.06.14 | By

The current intellectual property (IP) environment in Canada has caused increased friction with its closest allies, particularly in the area of IP rights protections for biopharmaceutical products. By revoking 19 patents since 2005 through questionable decisions, Canadian courts have set a disturbing precedent that risks future investments in cutting-edge R&D projects in innovative industries, and the high-paying jobs that accompany them.

Pages

Subscribe to RSS - Opinion